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Abstract
Background: Knowledge of the epidemiology of adverse drug events (ADEs) and medication errors in psychiatric
inpatients is limited outside Western countries. The nature of ADEs and medication errors are important for
improving the quality of care worldwide; therefore, we conducted the Japan Adverse Drug Events Study, a series of
cohort studies at several settings in Japan.
Methods: This report included 448 inpatients with 22,733 patient-days in a psychiatric hospital and psychiatric units
at a tertiary care teaching hospital over 1 year. Four psychiatrists and two other physicians reviewed all medical
charts and related documents to identify suspected incidents. The physicians later classified those incidents into
ADEs, potential ADEs, medication errors, or exclusions and evaluated the severity and preventability if the incidents
were events.
Results: During the study period, we identified 955 ADEs and 398 medication errors (incidence: 42.0 and 17.5 per
1000 patient-days, respectively). Among ADEs, 1.4 %, 28 %, and 71 % were life-threatening, serious, and significant,
respectively. Antipsychotics were associated with half of all ADEs. The incidence of medication errors was higher in
medical care units than in acute and nursing care units (40.9, 15.6, and 17.4 per 1000 patient-days, respectively). The
monitoring and ordering stages were the most common error stages (39 % and 34 % of all medication errors,
respectively), and 76 % of medication errors with ADEs were found at the monitoring stage. Non-psychiatric drugs
were three times as likely to cause ADEs with errors compared to psychiatric drugs.
Conclusions: Antipsychotic use, inadequate monitoring, and treatment of physical ailments by psychiatrists may
contribute to the high incidence of medication errors and ADEs among psychiatric inpatients in Japan. Psychiatrists
should be cautious in prescribing antipsychotics or unfamiliar medications for physical problems in their psychiatric
patients, and should monitor patients after medication administration.
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Background
Adverse drug events (ADEs) are drug-related injuries
resulting from medical intervention [1–3]. ADEs are
generally the most frequent cause of injuries due to
medical care in hospitals [4, 5]. Psychiatric inpatients are
at high-risk for these injuries because pharmacotherapy
plays a central role in psychiatric treatment [6, 7]. In
addition, many psychiatric patients present with comor-
bid medical disorders that require treatment with non-
psychiatric drugs, and when these conditions are treated
in psychiatric hospitals, this puts patients at further risk
for ADEs and medication errors [7, 8].
There is a need for more epidemiological data con-
cerning appropriate medication use in order to provide
safer and more effective pharmacological treatment for
psychiatric inpatients. Previous studies, however, have
noted the complexities of identifying ADEs and medica-
tion errors in psychiatric settings because it is difficult to
distinguish ADEs caused by drugs from symptoms re-
lated to mental disorders; in addition, it can be difficult
to define medication errors in these settings, as psychi-
atric pharmacotherapy often deviates from standard
treatment [9, 10]. In fact, there have been notably few
comprehensive studies on this topic, especially regarding
ADEs [7, 11–13]. Furthermore, the studies that have
been conducted all took place in Western countries,
meaning that their results cannot be generalized to clin-
ical settings in other countries without first assessing
local data [14], because mental health services differ be-
tween countries. For example, longer hospital stays and
lower staff ratios are two characteristics of Japanese psy-
chiatric care [15], while many African countries suffer
from a critical lack of psychiatrists and pharmacists [16].
To this end, we conducted a historical cohort study in
psychiatric settings to estimate the incidence and nature
of ADEs and medication errors among psychiatric inpa-
tients in Japan.
Methods
Study design and patient population
This historical cohort study was conducted as part of a
multicenter cohort study known as the Japan Adverse
Drug Events (JADE) Study [17, 18]. As part of the JADE
study series, we collected information using the standard
JADE protocol. [3, 17, 18] Data were collected from the
psychiatric inpatient units at one psychiatric hospital
and one tertiary care teaching hospital. There were a
total of 438 psychiatric inpatient beds between these two
hospitals, including beds in acute care units, nursing
care units, and medical care units. The acute care unit
comprises the main section of a psychiatric department
in which patients with an acute mental disorder receive
targeted mental care. Psychiatric patients who have re-
covered from the acute stage of their condition but who
still require nursing care are admitted to nursing care
units. Medical care units are specialized sections within a
psychiatric department that provide treatment to psychi-
atric patients with physical medical conditions. Both hospi-
tals included in this study used electronic medical records.
At the tertiary care teaching hospital, patients were
treated both by attending psychiatrists and by resident
psychiatrists, who have <3 years of training after obtain-
ing their medical license. Resident psychiatrists practiced
under the supervision of attending psychiatrists and pri-
marily ordered medications. In contrast, most of the psy-
chiatrists at the psychiatric hospital were attending
psychiatrists. Both hospitals admitted patients to the
acute care or medical care units within the psychiatry
department if psychiatric disorders were the main pre-
senting problem and the patients’ physical problems
were considered to be mild; internists provided medical
consultations as needed. Conversely, if patients’ physical
complications were considered to be more severe than
their psychiatric problems, or if patients required intensive
care (for example, as a result of myocardial infarction or
femoral fracture, or if they required intubation), they were
discharged from the psychiatric department and trans-
ferred to non-psychiatric wards for subsequent care.
Data were collected from all psychiatric inpatients
who were admitted to and discharged from the acute,
nursing and medical care units from April 1, 2010
through March 31, 2011. The main measures that were
evaluated were patient-days and the number of admis-
sions. The study was approved by the institutional re-
view boards of the Kyoto Prefectural University of
Medicine and by the institutional review boards of the
two participating hospitals. The need for informed con-
sent was waived because all data were collected as part
of the hospitals’ daily practices.
Definitions
The primary outcome measured in this study was the
number of ADEs, defined as drug-related injuries result-
ing from medical intervention [1, 2]. The term ADE has
a wide spectrum of definitions, including harm caused
by drugs at a usual dosage (adverse drug reactions:
ADRs) or at an unusual dosage, and also including harm
from dose reduction and discontinuation of drug therapy
[19]. For example, an extrapyramidal symptom, such as
akathisia, occurring after a patient receives antipsychotics,
and with no other apparent cause, is considered to be an
ADE. Rebound insomnia that occurs following discontinu-
ation of sedatives is another example of an ADE. An ADE
was then categorized by severity as fatal, life-threatening,
serious or significant. Fatal ADEs were those that resulted
in death. Life-threatening ADEs were those that caused
such issues as respiratory depression or suicidal behavior.
Serious ADEs included gastrointestinal bleeding, falls, or a
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decrease in blood pressure. Significant ADEs included cases
with milder symptoms, such as diarrhea, constipation,
extrapyramidal symptoms or drowsiness.
A secondary outcome that was measured in this study
was medication errors. Medication errors could occur at
any step of the medication use process (ordering, tran-
scribing, dispensing, administering or monitoring), and
medication errors may or may not cause ADEs. If a medi-
cation error was found, the type of error and the stage in
the process where it occurred were classified. The medica-
tion use process included the following stages: ordering by
psychiatrists or other physicians; transcription by nurses;
dispensing by pharmacists (or by psychiatrists and nurses,
as was the case during the night shift and on weekends in
the psychiatric hospital); administration by nurses or by
patients; and monitoring by psychiatrists, other health
professionals or by patients themselves.
ADEs were categorized as either preventable or non-
preventable. An ADE was considered to be preventable if it
resulted from a medication error or was otherwise amelio-
rable by available means (e.g., switching to a different drug
or cautious monitoring after administration). An ADE that
occurred in the absence of a medication error was defined
as a non-preventable ADE. For example, a rash that oc-
curred due to lamotrigine use in a patient without a history
of lamotrigine-induced rash would not be considered a
preventable ADE, but it would be considered as a prevent-
able ADE if the patient had a history of such a rash.
We also classified ADEs according to their potential
for causing injury. A potential ADE was an error that
had the potential for injury but did not actually result in
injury, either because of specific circumstances, chance,
or because the error was intercepted. For example, if
hypnotics were administered several hours earlier than
prescribed, this would constitute a medication error and
potential ADE, even if no negative effects were observed
because hypnotics may cause immediate somnolence. On
the other hand, early administration of anti-dementia drugs
would be classified as a medication error but not a poten-
tial ADE because the drug rarely causes acute side effects.
Data collection and classification
The definitions and methods used in this study were
consistent with those from prior studies on this topic
[3, 17, 18]. In this study, four psychiatrists and two physi-
cians, all with experience in the classification of ADEs as a
result of previous research on this topic, reviewed all pa-
tient charts from each participating hospital, along with la-
boratory results, incident reports and prescription queries.
Research assistants used patient charts to compile demo-
graphic characteristics and administrative data for all
enrolled patients in the cohort.
Once all data were collected from participating hospitals,
the reviewers independently classified relevant incidents as
an ADE, potential ADE or medication error, while also re-
cording the details of those incidents. This included infor-
mation about the name, dose, route and class of the drugs,
the details of symptoms resulting from ADEs, and the de-
tails related to medication errors such as type, stage and
persons who were in charge at the time the error occurred.
The reviewers also independently classified all incidents ac-
cording to their severity and preventability. After all sus-
pected incidents were collected, the reviewers met to
confirm the final classification for each incident. When the
reviewers disagreed on the classification of an incident,
they reached a consensus through discussion.
Statistical analyses
The incidences per 1000 patient-days, crude rates per 100
admissions, and 95 % confidence intervals (CIs) were calcu-
lated as a whole and by unit types (acute care unit, nursing
care unit, and medical care unit). Continuous variables are
presented as means with standard deviations (SDs) or me-
dians with interquartile ranges (IQRs), and categorical vari-
ables are shown as numbers and percentages. We used the
χ2 test to assess the relationship between drug classes and
preventable ADEs. We calculated inter-rater reliabilities
using k statistics. Kappa scores between reviewers regarding
the presence of an ADE were 0.96 (ADE v. potential ADE
or exclude). The kappa for preventability was 0.95 (prevent-
able v. non-preventable), while the kappa for severity was
0.43 (significant v. serious or life-threatening). These values
were similar to those published in previous reports by
Rothschild et al. (2007) and Morimoto et al. (2011). We
performed all analyses using JMP V.11.2 (SAS Institute,
Cary, North Carolina, USA) software.
Results
There were a total of 448 admissions with 22,733
patient-days during the study period. The ages of the in-
cluded patients ranged from 13 to 97 years old, and the
mean age was 56 (SD 22) years. Forty-one (185/448) per-
cent of patients were aged ≥65 years, and 247 (55 %)
were female. The median hospital stay was 32 (inter-
quartile range 15–75) days. The acute care, nursing care
and medical care units admitted 341 (76 %), 75 (17 %),
and 32 (7 %) patients, respectively (Table 1). Of all ad-
missions, approximately 42 % were involuntary admis-
sions. The most common reasons for admission were
schizophrenic disorders and dementia, and the median
number of medications patients were taking on admis-
sion was 6 (range 4–8) (Table 1).
Adverse drug events
We identified 1234 suspected incidents, and through re-
views and discussions of these suspected incidents, we
identified 955 ADEs among 283 patients (63 %) (Fig. 1).
The incidence of ADEs was 42.0 [95 % CI 39.4–44.6] per
Ayani et al. BMC Psychiatry  (2016) 16:303 Page 3 of 8
1000 patient-days, and the crude rate was 213 [95 % CI
184–243] per 100 admissions (Table 2). Significant ADEs
accounted for 71 % (677 events in 263 patients) of all
events, followed by serious ADEs (28 %, 265 in 124) and
life-threatening ADEs (1.4 %, 13 in 12). There were no
fatal ADEs that occurred during the study.
The most common class of drugs associated with
ADEs was atypical antipsychotics (34 %, 323/955), and
almost half of ADEs (46.9 %, 448/955) were associated
with typical and atypical antipsychotics. Non-psychiatric
drugs accounted for 16 % (124/789) of non-preventable
ADEs, but were associated with 42 % (69/166) of all
preventable ADEs. In other words, the proportion of
preventable ADEs to all ADEs associated with non-
psychiatric drugs (69 per 193 ADEs; 36 %) was higher
compared to psychiatric drugs (97 per 762 ADEs; 13 %)
(P < 0.001) (Table 3).
When ADEs were assessed by organ system, central
nervous system symptoms (including falls, over-sedation
and extrapyramidal symptoms) were the most frequent
symptoms, accounting for 44 % (415/995) of all ADEs,
followed by gastrointestinal symptoms (including diar-
rhea and constipation) (34 %, 326/955), allergic or skin
symptoms (including drip leakage) (6 %, 58/955) and
metabolic or liver dysfunction (5 %, 49/955).
Medication errors and potential adverse drug events
We identified 398 medication errors among 174 patients
(39 %). The incidence was 17.5 [95 % CI 15.8–19.2] per
1000 patient-days, and the crude rate was 88.8 [95 % CI
72.9–105] per 100 admissions. Among the 398 medica-
tion errors, 166 actually resulted in ADEs and were
therefore classified as preventable ADEs, whereas 186
had the potential to cause injury but did not result in
observed harm (Fig. 1). The incidence and crude rates
were approximately two times higher in the medical care
units compared to the other units. Furthermore, the
Table 1 Demographic data for the study population
Factors No. of patients
Total (n = 448)
Age≥ 65 years, n (%) 185 (41)
Female, n (%) 247 (55)




Admission pathway, n (%)
Scheduled admission 247 (55)
Emergency admission 201 (45)
Nonresident physician in charge, n (%) 379 (85)
Involuntary admission, n (%) 186 (41.5)
Number of prescribed medications on admission,
median (quartile)
6 (4–8)
Primary diagnosis,a n (%)
Dementia 97 (21.7)
Other organic disorders 19 (4.2)
Mental or behavioral disorder due to substance use 48 (10.7)
Schizophrenia and other psychotic disorders 113 (25.2)
Mood disorders 84 (18.8)
Depression 38 (8.5)
Mania, Bipolar disorder 32 (7.1)
Other mood disorders 14 (3.1)
Neurotic, stress-related and somatoform disorders 40 (8.9)
Anorexia 17 (3.8)
Mental retardation 11 (2.5)
Development disorder 12 (2.7)
Other 7 (1.6)





955 (283 patients) 




Adverse Drug Events 
with Medication Errors 
166 (79 patients)
Fig. 1 Relationship between adverse drug events and medication errors
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incidence of preventable ADEs in the medical care units
(29.6) was much higher compared to the acute care
units (5.1) and nursing care units (8.5) (Table 2).
The incidence of preventable ADEs and non-preventable
ADEs was 7.3 [95 % CI 6.2–8.4] and 34.7 [95 % CI 32.3–
37.1] per 1000 patient-days, respectively. Thus, 17.4 %
(166/955) of ADEs were considered preventable. The inci-
dence of potential ADEs was 8.2 [95 % CI 7.0–9.4] per
1000 patient-days. Forty-six medication errors were deter-
mined to carry no risk of injury to patients, so these errors
were not considered to be potential ADEs. Twelve percent
of potential ADEs (23 cases) were intercepted before a
drug was administered and were thus classified as inter-
cepted potential ADEs. Medication errors were most
frequently associated with the monitoring stage (39 %, 155/
398) and ordering stage (34 %, 134/398) of treatment. In
addition, 76 % (126/166) of preventable ADEs occurred
during the monitoring stage. Potential ADEs occurred
most frequently during the ordering stage, accounting
for 46 % (86/186) of all potential ADEs, followed by
the administering stage (36 %, 67/186).
Discussion
We determined that ADEs and medication errors were
common in Japanese psychiatric inpatient settings. ADEs
were observed in 63 % of psychiatric inpatients with an
incidence of 42 per 1000 patient-days, and medication
errors were observed in 39 % of inpatients with an inci-
dence of 17.5 per 1000 patient-days. Most of these ADEs
were not preventable (83 % of ADEs), and 29 % of ADEs
were classified as serious or life-threatening. In addition,
we identified frequent medication errors at the monitor-
ing stage (39 % of all medication errors), and this was
more evident for preventable ADEs (76 % of all prevent-
able ADEs occurred at this stage).
Comparison with findings from previous studies in
psychiatric settings
Although there have been several previous studies on ADEs
(or ADRs) and medication errors in psychiatric settings,
comparisons between the previous studies were difficult
because they used different designs and denominators [20].
In addition, among studies utilizing the same denominator
but with different study designs, there were significant
differences in the reported rates of medication errors (e.g.,
0.79 potential ADEs per 1000 patient-days based on a
reporting system [21] vs. 1516 medication errors per 1000
patient-days on a retrospective chart review [8]). Therefore,
in order to compare our findings with those of previous
studies in different settings, we adopted the same definition
and methodology used in the study performed by Roth-
schild et al., which took place in psychiatric settings in the
USA [7], as well as those of other studies in general settings
in the USA [2] and Japan [17]. In comparison with the
present study, Rothschild et al. reported one-quarter
incidence of ADEs (10 per 1000 patient-days) and one-
third medication errors (6.3 per 1000 patient-days). The dif-
ference become even more evident regarding the crude rate
of ADEs per 100 admissions (213 v. 10.2) and medication
errors (88.8 v. 6.4); this is likely a result of the fact that the
mean length of stay is much longer in Japan compared to
the USA (50.7 v. 10.3 days).
Table 2 Incidences of adverse drug events, medication errors and preventable adverse drug events
Unit n Patient-days ADEs Incidencea 95 % CI Crude rateb 95 % CI
Acute 341 16834 725 43.1 40.0–46.1 213 179–246
Nursing 75 4480 157 35.0 29.7–40.4 209 144–275
Medical 32 1419 73 51.4 40.0–62.9 228 88.6–368
Total 448 22733 955 42.0 39.4–44.6 213 184–243
Unit n Patient-days Medication Errors Incidencea 95 % CI Crude rateb 95 % CI
Acute 341 16834 262 15.6 13.7–17.4 76.8 62.0–91.7
Nursing 75 4480 78 17.4 13.6–21.2 104 56.3–152
Medical 32 1419 58 40.9 30.6–51.2 181 73.4–289
Total 448 22733 398 17.5 15.8–19.2 88.8 72.9–105
Unit n Patient-days Preventable ADEs Incidencea 95 % CI Crude rateb 95 % CI
Acute 341 16834 86 5.1 4.0–6.2 25.2 16.4–34.1
Nursing 75 4480 38 8.5 5.8–11.2 50.7 17.5–83.8
Medical 32 1419 42 29.6 20.8–38.4 131 35.9–227
Total 448 22733 166 7.3 6.2–8.4 37.1 25.8–48.3
ADEs adverse drug events, CI confidence interval
aPer 1000 patient-days
bPer 100 admissions
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The reasons for the higher incidence of ADEs in the
present study may result from differences inpatient char-
acteristics between this study and the USA study. The
most common diagnosis in the USA study was mood
disorders (66.4 %), while schizophrenic disorder (25 %)
followed by dementia (22 %) were the most common
disorders in the present study. In accordance with this
finding, Schmidt et al. (1984) reported a similar rate of
ADRs (346 per 100 admissions) in a previous study per-
formed in Germany in which schizophrenic disorder was
the most common diagnosis (37 %) [11], and Hermesh
et al. (1985) reported that elderly patients with organic
brain disorders were at high risk of ADRs [12].
Differences of the medical system in the treatment of
physical complications in psychiatric inpatients may be
another possible reason for the discrepancy between our
findings and prior reports on this topic. Patients in psy-
chiatric settings in Japan tend to receive more extensive
treatments for physical complications compared to pa-
tients in the USA, where patients with severe physical
complications are commonly transferred to a general-
care setting, especially in cases that require electrocar-
diographic monitoring or a continuous intravenous drip
[7]. As a result, patients in Japanese inpatient psychiatric
units may be at higher risk of ADEs and medication er-
rors, as prescribing unfamiliar drugs is associated with














potential ADEs, n (%)
(n = 23)
Non-intercepted
potential ADEs, n (%)
(n = 163)
Antibiotics 10 (1.0) 0 (0) 10 (1.3) 2 (1.1) 0 (0) 2 (1.2)
Antihypertensives 14 (1.5) 3 (1.8) 11 (1.4) 7 (3.8) 1 (4.3) 6 (3.7)
Cardiovascular drugs 8 (0.8) 1 (0.6) 7 (0.9) 12 (6.5) 2 (8.7) 10 (6.1)
Anticoagulants 9 (0.9) 2 (1.2) 7 (0.9) 1 (0.5) 0 (0) 1 (0.6)
Antihyperlipidemics 1 (0.1) 0 (0) 1 (0.1) 0 (0) 0 (0) 0 (0)
Antidiabetics 10 (1.0) 2 (1.2) 8 (1.0) 9 (4.8) 1 (4.3) 8 (4.9)
Peptic ulcer drugs 1 (0.1) 0 (0) 1 (0.1) 0 (0) 0 (0) 0 (0)
Laxatives 40 (4.2) 10 (6.0) 30 (3.8) 7 (3.8) 0 (0) 7 (4.3)
NSAIDs 6 (0.6) 0 (0) 6 (0.8) 7 (3.8) 0 (0) 7 (4.3)
Antiallergic agents 2 (0.2) 0 (0) 2 (0.3) 0 (0) 0 (0) 0 (0)
Electrolytes or fluids 58 (6.1) 50 (30.1) 8 (1.0) 21 (11.3) 1 (4.3) 20 (12.3)
Chinese herbal medicines 2 (0.2) 0 (0) 2 (0.3) 0 (0) 0 (0) 0 (0)
Sedatives (benzodiazepine) 66 (6.9) 28 (16.9) 38 (4.8) 53 (28.5) 0 (0) 53 (32.5)
Sedatives (other) 15 (1.6) 4 (2.4) 11 (1.4) 5 (2.7) 1 (4.3) 4 (2.5)
Anxiolytics 31 (3.2) 6 (3.6) 25 (3.2) 5 (2.7) 2 (8.7) 3 (1.8)
Antidepressants (SSRI, SNRI, NaSSA) 58 (6.1) 2 (1.2) 56 (7.1) 4 (2.2) 3 (13.0) 1 (0.6)
Antidepressants (other) 62 (6.5) 6 (3.6) 56 (7.1) 1 (0.5) 1 (4.7) 0 (0)
Mood stabilizers 45 (4.7) 14 (8.4) 31 (3.9) 4 (2.2) 2 (8.7) 2 (1.2)
Antipsychotics (atypical) 323 (33.8) 32 (19.3) 291 (36.9) 34 (18.3) 6 (26.1) 28 (17.2)
Antipsychotics (typical) 125 (13.1) 4 (2.6) 121 (15.3) 1 (0.5) 0 (0) 1 (0.6)
Anticonvulsants 8 (0.8) 1 (0.6) 7 (0.9) 3 (1.6) 0 (0) 3 (1.8)
Anti-parkinsonian drugs 24 (2.5) 0 (0) 24 (3.0) 1 (0.5) 0 (0) 1 (0.6)
Anti-dementia medicines 5 (0.5) 0 (0) 5 (0.6) 1 (0.5) 1 (4.3) 0 (0)
Other drugs 32 (3.4) 1 (0.6) 31 (3.9) 8 (4.3) 2 (8.7) 6 (3.7)
Psychiatric drugsa 762 (79.8) 97 (58.4) 665 (84.3) 112 (60.2) 16 (69.6) 96 (58.9)
Non-psychiatric drugsb 193 (20.2) 69 (41.6) 124 (15.7) 74 (39.8) 7 (30.4) 67 (41.1)
All drugs 955 (100) 166 (100) 789 (100) 186 (100) 23 (100) 163 (100)
ADEs adverse drug events, NSAIDs nonsteroidal anti-inflammatory drugs, SSRI selective serotonin reuptake inhibitor; SNRI serotonin-noradrenaline reuptake
inhibitor, NaSSA noradrenergic and specific serotonin antidepressants
aPsychiatric drugs include: sedatives (benzodiazepine), sedatives (other), anxiolytics, antidepressants (SSRI, SNRI, NaSSA), antidepressants (other), mood stabilizers,
antipsychotics (atypical), antipsychotics (typical), anticonvulsants, anti-parkinsonian drugs and anti-dementia medicines
bNon-psychiatric drugs include: antibiotics, antihypertensives, cardiovascular drugs, anticoagulants, antihyperlipidemics, antidiabetics, peptic ulcer drugs, laxatives,
NSAIDs, antiallergic agents, electrolytes or fluids, Chinese herbal medicines and other drugs
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medication errors due to lack of experience and know-
ledge for practitioners in both psychiatric and general
settings [7, 22]. In the present study, the proportion of
preventable ADEs associated with non-psychiatric drugs
was three times higher compared to psychiatric drugs
(36 % v. 13 %, respectively), and the incidence of pre-
ventable ADEs was higher in the medical care units
compared to acute and nursing care units (27.5 v. 5.1 v.
9.2 per 1000 patient-days, respectively).
Comparison to general-care settings in Japan
Compared with a previous study on ADEs in general-
care settings in Japan [17], we also found a higher inci-
dence of ADEs (42.0 v. 17.0 per 1000 patient-days) and
medication errors (17.5 v. 8.7 per 1000 patient-days).
The higher incidence of ADEs and medication errors in
psychiatry units may result from the specific complex-
ities of the medications used to treat psychiatric patients.
Our results demonstrated that almost half of ADEs were
associated with antipsychotics, which is in accordance
with previous studies that also found that antipsychotics
were the drug class most frequently associated with
ADEs [7, 11, 13]. Antipsychotics are prescribed for many
patients—not only for the treatment of schizophrenia
but also for sedation in agitated patients—and they may
cause a wide range of ADEs, including neurological,
gastrointestinal, cardiovascular, metabolic and endocrine
symptoms. The frequency and intensity of ADEs result-
ing from the use of antipsychotics (especially when used
at high dosages for patients with severe mental disor-
ders) may contribute to the high incidence of ADEs in
psychiatric units. In addition, psychiatric patients with
severe mental disorders may lack self-awareness, and as
a result, they may not be able to fully report their symp-
toms due to ADEs to medical staff. Furthermore, if they
unexpectedly refuse to take their medications, this may
cause more frequent medication errors. Finally, monitor-
ing errors may occur due to a combination of lack of ex-
perience and knowledge regarding the management of
physical complications on the part of psychiatrists as
well as inadequate staffing in psychiatric units [15].
Clinical implications
Psychiatrists usually regard ADEs like constipation from
antipsychotics and drowsiness from sedatives as com-
mon and unavoidable consequences of medication, and
believe that such ADEs seldom cause serious outcomes.
However, serious ADEs are not rare, even though only a
small percentage of ADEs are serious because ADEs
occur frequently in medical care. According to the re-
sults of this research, life-threatening and serious ADEs
accounted for 1.4 % (13 events in 12 patients) and 28 %
(265 events in 124 patients) of events, respectively. Psy-
chiatrists sometimes have to decide whether or not to
continue administering medications associated with ADEs
to treat patients with serious mental conditions; therefore,
it is important to identify ADEs at an earlier stage to pre-
vent serious events or to ameliorate their severity.
Moreover, as demonstrated by the results of the
present study, psychiatrists were likely to make medica-
tion errors with ADEs during physical treatments, espe-
cially during the monitoring stage. This may be because
psychiatrists focus on psychiatric problems and are less
likely to treat physical problems, especially in psychiatric
settings. Physicians usually tend to keep psychiatric in-
patients at a distance, and psychiatrists in Japan may
thus have to treat physical complications, with the ex-
ception of very severe physical conditions. Fragmenta-
tion of the physical and mental health systems is one of
the barriers that hinders patients from receiving ad-
equate care; [23] therefore, fixing the fragmented sys-
tems and increasing communication between physicians
and psychiatrists could improve patients’ physical health
and minimize injury from medications among psychi-
atric inpatients in Japan and other countries.
Study limitation and strengths
Our study had several limitations. First, we conducted
this study at one psychiatric hospital and one tertiary
care teaching hospital. Therefore, our results may not
represent other hospitals, although we attempted to
mitigate this limitation by including both a psychiatric
hospital and a tertiary care teaching hospital to represent
a wide range of psychiatric settings. Second, we could
not estimate the incidence and nature of ADEs and
medication errors caused by doctors with other special-
ties in psychiatric settings because almost all medica-
tions were prescribed by psychiatrists in this study.
Third, some ADEs and medication errors may have been
missed, which would mean that our results underestimate
the true incidence. However, we were able to precisely
evaluate and collect data on confirmed incidents, espe-
cially physical symptoms due to ADEs; this was because
internists with experience in the classification of ADEs as
a result of previous research on this topic [17, 18] played a
leading role in this study. In addition, more robust alterna-
tives for measuring ADEs and medication errors have not
yet been developed, and the approach we used is the ap-
proach that is currently used most widely, suggesting that
the figures obtained in this study are the best that are cur-
rently available.
Conclusions
We found high incidences of ADEs and medication er-
rors in general psychiatric settings and identified some
risk factors for ADEs, including prescription of antipsy-
chotics and treatment during the monitoring stage after
drugs are administered. Therefore, clinicians should be
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cautious in prescribing antipsychotics and while moni-
toring patients after administration, especially when pa-
tients are unable to report their symptoms due to a
severe mental condition. Furthermore, because of the
higher risk of ADEs and medication errors during the
treatment of physical complications, consultation with
physicians in other departments is essential when psy-
chiatrists are considering prescribing unfamiliar medica-
tions for physical problems in their psychiatric patients.
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